Astellas Pharma’s Breakthrough Drug Approved by FDA to Ease Menopausal Symptoms
Astellas Pharma, a Tokyo-based pharmaceutical company, has achieved a significant milestone with the approval of its groundbreaking drug by the U.S. Food and Drug Administration (FDA). The drug, fezolinetant, has been given the green light to treat hot flashes and night sweats caused by menopause, making it the first therapy to target a specific receptor in the central nervous system for alleviating these symptoms. The Disruptive Symptoms Hot flashes and night sweats are among the most distressing and disruptive symptoms experienced by women going through menopause. As estrogen and progesterone production decline during this transitional phase of life, the resulting hormonal imbalance can trigger sudden and intense feelings of warmth, affecting body temperature regulation. While hormone therapy has traditionally been the go-to treatment for these vasomotor symptoms, it carries potential risks, such as increased chances of stroke, blood clots, or heart attack. Furthermore, women w...